<?xml version="1.0" encoding="UTF-8"?>
<p>Although limitations of clinical studies require further confirmation, Ï‰-3 PUFA intake produced significant clinical benefits and reduction of the symptoms in patients with autoimmune disorders, especially rheumatic diseases and systemic lupus erythematosus [
 <xref rid="B195-vaccines-08-00468" ref-type="bibr">195</xref>,
 <xref rid="B196-vaccines-08-00468" ref-type="bibr">196</xref>,
 <xref rid="B197-vaccines-08-00468" ref-type="bibr">197</xref>]. In support, low levels of PUFAs have been found in the serum of patients with rheumatic diseases [
 <xref rid="B198-vaccines-08-00468" ref-type="bibr">198</xref>]. Conversely, inconsistent results are reported for multiple sclerosis, thus the possible usefulness of these fatty acids as supportive therapy requires more clinical trials [
 <xref rid="B199-vaccines-08-00468" ref-type="bibr">199</xref>]. 
</p>
